The University of Chicago Header Logo

Connection

Richard A. Larson to Drug Therapy, Combination

Back to Details
This is a "connection" page, showing publications Richard A. Larson has written about Drug Therapy, Combination.
Richard A. Larson
Connection Strength
0.161
Drug Therapy, Combination
  1. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012 Aug; 70(2):345-50.
    View in: PubMed
    Score: 0.088
  2. Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv. 2018 12 26; 2(24):3608-3617.
    View in: PubMed
    Score: 0.035
  3. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018 12 27; 379(26):2517-2528.
    View in: PubMed
    Score: 0.035
  4. Nonrandom chromosome abnormalities in angioimmunoblastic lymphadenopathy. Blood. 1982 Oct; 60(4):877-87.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.